InMed Pharmaceuticals (INM) Assets (2020 - 2026)

InMed Pharmaceuticals' Assets history runs 7 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• On a quarterly basis, Assets fell 1.57% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 1.57% decrease from a year earlier, with the FY2025 full-year figure at $15.6 million, up 31.78% from the prior year.
• Assets declined to $9.1 million in Q1 2026 per INM's latest filing, from $11.2 million in the prior quarter.
• Across five years, Assets topped out at $16.9 million in Q4 2022 and bottomed at $8.5 million in Q4 2024.
• The 5-year median for Assets is $13.4 million (2024), against an average of $12.8 million.
• Across the five-year window, Assets plunged 44.27% in 2024 and surged 31.78% in 2025, its largest moves.
• Year by year, Assets stood at $16.9 million in 2022, then retreated by 9.84% to $15.3 million in 2023, then plunged by 44.27% to $8.5 million in 2024, then surged by 31.63% to $11.2 million in 2025, then decreased by 18.39% to $9.1 million in 2026.
• Per Business Quant, the three latest INM Assets figures stand at $9.1 million (Q1 2026), $11.2 million (Q4 2025), and $13.4 million (Q3 2025).